BiotechTube

Vancomycin + Fidaxomicin

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Clostridium Difficile Infection

Conditions

Clostridium Difficile Infection

Trial Timeline

Oct 17, 2012 → Dec 15, 2014

NCT ID
NCT01818141

About Vancomycin + Fidaxomicin

Vancomycin + Fidaxomicin is a approved stage product being developed by Merck for Clostridium Difficile Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01818141. Target conditions include Clostridium Difficile Infection.

What happened to similar drugs?

8 of 20 similar drugs in Clostridium Difficile Infection were approved

Approved (8) Terminated (5) Active (12)
✅Fidaxomicin + Vancomycin + PlaceboAstellas PharmaApproved
✅Fidaxomicin + VancomycinAstellas PharmaApproved
✅Fidaxomicin + VancomycinMerckApproved
✅bezlotoxumab + Vancomycin OralMerckApproved
✅Fidaxomicin 200 mg + Placebo + VancomycinMerckApproved
✅BezlotoxumabMerckApproved
✅TEICOPLANINSanofiApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01818141ApprovedCompleted

Competing Products

20 competing products in Clostridium Difficile Infection

See all competitors
ProductCompanyStageHype Score
Metronidazole + Metronidazole-DRF1 + Metronidazole-DRF2Dr. Reddy's LaboratoriesPhase 2
32
Fidaxomicin + Vancomycin + PlaceboAstellas PharmaApproved
35
Fidaxomicin + Treatment for CDI other than fidaxomicin TypeAstellas PharmaPre-clinical
26
OPT-80 + vancomycinAstellas PharmaPhase 3
40
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsulesAstellas PharmaPhase 3
40
Fidaxomicin + VancomycinAstellas PharmaApproved
43
Fidaxomicin + VancomycinMerckApproved
43
fidaxomicin + PlaceboMerckPhase 3
40
Surotomycin + PlaceboMerckPhase 1
29
CB-183,315 + Placebo + VancomycinMerckPhase 2
35
Surotomycin + PlaceboMerckPhase 1
29
MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
40
FidaxomicinMerckPre-clinical
18
Bezlotoxumab + Standard CDI treatmentMerckPre-clinical
26
MK-3415 + MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
40
Fidaxomicin + Vancomycin + Matching Placebo to FidaxomicinMerckPhase 3
40
bezlotoxumab + Vancomycin OralMerckApproved
43
Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD)MerckPhase 3
40
Bezlotoxumab Injection [Zinplava]MerckPre-clinical
26
PAR-101/OPT-80 + VancomycinMerckPhase 3
40